Interleukin 2-antibody and tumor necrosis factor-antibody fusion proteins induce different antitumor immune responses in vivo

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1385-1397

  Christ, Oliver ^a   Matzku, Siegfried ^b,c   Burger, Christa ^b   Zöller, Margot ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MERCK KGAA   (Germany)

^c UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; HYBRID PROTEIN; INTERLEUKIN 2; RECOMBINANT ANTIBODY; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; LYMPHOKINE ACTIVATED KILLER CELL; LYMPHOMA CELL LINE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; HUMANS; IMMUNITY; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, SCID; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034896456     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Human tumor antigens recognized by T cells: New perspectives for anticancer vaccines
2. Tumor antigens recognized by T lymphocytes
3. The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes
4. Tumor-specific immune response: Current in vitro analyses may not reflect the in vivo immune status
5. Activation of cytotoxic T cells by solid tumors
6. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: Effects of tumor cells and their supernatants on proliferative responses of lymphocytes
7. Tumor-reactive T cells accumulate in lung cancer tissue but fail to respond due to tumor cell derived factor
8. Lessons from T cell responses to virus-induced tumors for cancer eradication in general
9. Accessory molecules and costimulation requirements for CD4 T cell response
10. Costimulation of T cells for tumor immunity
11. Immunotherapy. II. Antigens, receptors and costimulation
12. Recombinant interleukin-2-based treatments for advanced melanoma: The experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group Cancer
13. Vascular leak syndrome: A side effect of immunotherapy
14. 2nd interleukin 1 trials in cancer patients: A review of the toxicity, antitumor and hematopoietic effects
15. Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2
16. Major histocompatibility complex class II+/B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice
17. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2
18. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines
19. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
20. Retrovirus-mediated gene transfer of B7-1 and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic one
21. Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: A novel approach to tumor immunotherapy
22. Targeting cancer therapy
23. Targeting of peripheral blood T lymphocytes
24. Single-chain Fv antibodies for targeting cancer therapy
25. Stimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene
26. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing
27. Human melanoma therapy in the SCID mouse: Targeting and activation of melanoma-specific cytotoxic T cells by bispecific antibody fragments is curative
28. Single-chain antibodies in pancreatic cancer
29. Superantigen-targeted therapy: Phase I escalating repeat dose trial of the fusion protein PNU-214565 in patients with advanced gastrointestinal malignancies
30. Endothelial cells expressing an inflammatory phenoltype are lysed by superantigen-targeted cytotoxic T cells
31. Perforin and IFN-γ are involved in the antitumor effects of antibody-targeted superantigens
32. Repeated treatment with antibody-targeted superantigens strongly inhibits tumor growth
33. Immunotherapy of human colon cancer by antibody-targeted superantigens
34. Superantigen-based immunotherapy: A Phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxic A recombinant fusion protein, in advanced pancreatic and colorectal cancer
35. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins
36. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody
37. Tumor-targeted IL-2 amplifies, T cell-mediated response induced by gene therapy with single-chain IL-12
38. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response
39. Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule
40. Antibody targeted interleukin 2 stimulates T-cell killing of autologous tumor cells
41. A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake
42. A single chain IL-12 antibody fusion protein retains specificity and IL-12 bioactivity and demonstrates antitumor activity
43. Activation of human effector cells by a tumor reactive recombinant antiganglioside GD2 interleukin-2 fusion protein
44. Targeting γ interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells
45. A fusion protein of IL-8 and a Fab antibody fragment binds to IL-8 receptors and induces neutrophil activation
46. Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein
47. Tumor necrosis factor α and toxicology
48. Tumour necrosis factor: Strategies for improving the therapeutic index
49. Tumor necrosis factor: Function, release, and clearance
50. Tumor necrosis factor as an antineoplastic agent: Pitfalls and promises
51. Enhancing effect of tumor necrosis factor (TNF)-α, but not IFN-γ, on the tumor-specific cytotoxicity of γ/δ T cells from glioblastoma patients
52. Tumor necrosis factor α-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors
53. Regression of human breast cancer xenografts in response to intralesional treatment with interferons α and γ potentiated by tumor necrosis factor
54. Tumor necrosis factor α-induced leukocyte adhesion in normal and tumor vessels: Effect of tumor type, transplantation site, and host strain
55. Biological response modulation by tumor necrosis factor α (TNF α) in a Phase Ib trial in cancer patients
56. Retroviral vector-mediated transfer of the tumor necrosis factor α gene into human cancer cells restores an apoptotic cell death program and induces a bystander-killing effect
57. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-α induces significant tumor regression
58. Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy
59. Antigen expression of metastasizing and nonmetastasizing human melanoma cells xenografted into nude mice
60. Melanocyte lineage specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
61. Humanization of a mouse monoclonal antibody by CDR-grafting: The importance of framework residues on loop conformation
62. Dendritic cells differentiated from human monocytes through a combination of IL-4, GM-CSF, and IFN-γ exhibit phenotype and function of blood dendritic cells
63. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy
64. In silico generation of tissue-specific and promiscuous HLA ligand databases using chips and virtual HLA class II matrices
65. Improved engraftment of human tumours in SCID mice pretreated with radiation and anti-asialo GM1
66. Synergy between an antiangiogenic integrin α antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases
67. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice
68. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins
69. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow
70. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2
71. Effector cell targeting by bispecific antibodies in the therapy of human malignant melanoma: Evaluation in the SCID mouse model
72. Cytokines and macrophages
73. TNF, immunity, and inflammatory disease: Lessons of the past decade
74. Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases
75. Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2
76. Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice